[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fGLCFDCSNKunA9m7E60VSm5_16ckskxDieaScCg215LU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":33,"phaseBuckets":49,"rows":56},"Istituto Clinico Humanitas",[4,6],"Istituto Clinico Humanitas Mater Domini",279,false,60,5,578566,4,238,[15,18,21,23,25,27,29,31],{"name":16,"count":17},"Colorectal Cancer",8,{"name":19,"count":20},"Infertility",7,{"name":22,"count":20},"Lung Cancer",{"name":24,"count":10},"Bladder Cancer",{"name":26,"count":10},"Pancreatic Cancer",{"name":28,"count":10},"Breast Cancer",{"name":30,"count":10},"ART",{"name":32,"count":10},"Surgery",[34,39,44],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06892223","Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation","2025-03-01","Monalizumab",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06918912","Study of Loncastuximab Tesirine in Patients With Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure","2025-03-04","Loncastuximab Tesirine",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04624828","Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT","2026-07","androgen deprivation therapy",[50,51,52,53,54,55],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[57,85,109,132,150,178,196,220,245,274,292,329,355,381,417,444,462,488,514,542,560,578,604,622,650,668,693,717,741,771,794,820,844,870,896,921,946,972,995,1019,1046,1071,1095,1124,1148,1173,1198],{"intervention":43,"totalTrials":58,"cells":59},1,{"EARLY_PHASE1":60,"PHASE1":63,"PHASE2":65,"PHASE3":79,"PHASE4":81,"NA":83},{"trials":61,"activeCount":62},[],0,{"trials":64,"activeCount":62},[],{"trials":66,"activeCount":58,"soonestReadout":42},[67],{"nctId":40,"briefTitle":41,"status":68,"phases":69,"primaryCompletion":42,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":78},"RECRUITING",[52],"2027-06","2023-06-16",50,[74,75,76,77],"Diffuse Large B-Cell Lymphoma","High-grade B-cell Lymphoma (HGBCL)","B-Cell Lymphoma Treatment","Relapsed or Refractory Lymphoma",[43],{"trials":80,"activeCount":62},[],{"trials":82,"activeCount":62},[],{"trials":84,"activeCount":62},[],{"intervention":38,"totalTrials":58,"cells":86},{"EARLY_PHASE1":87,"PHASE1":89,"PHASE2":91,"PHASE3":103,"PHASE4":105,"NA":107},{"trials":88,"activeCount":62},[],{"trials":90,"activeCount":62},[],{"trials":92,"activeCount":58,"soonestReadout":37},[93],{"nctId":35,"briefTitle":36,"status":68,"phases":94,"primaryCompletion":37,"completion":95,"start":96,"enrollment":97,"conditions":98,"interventions":102},[52],"2026-12","2021-12-03",42,[99,100,101],"Acute Myeloid Leukaemia","MDS (Myelodysplastic Syndrome)","MPN (Myeloproliferative Neoplasms)",[38],{"trials":104,"activeCount":62},[],{"trials":106,"activeCount":62},[],{"trials":108,"activeCount":62},[],{"intervention":48,"totalTrials":58,"cells":110},{"EARLY_PHASE1":111,"PHASE1":113,"PHASE2":115,"PHASE3":117,"PHASE4":119,"NA":121},{"trials":112,"activeCount":62},[],{"trials":114,"activeCount":62},[],{"trials":116,"activeCount":62},[],{"trials":118,"activeCount":62},[],{"trials":120,"activeCount":62},[],{"trials":122,"activeCount":58,"soonestReadout":47},[123],{"nctId":45,"briefTitle":46,"status":124,"phases":125,"primaryCompletion":47,"completion":47,"start":126,"enrollment":127,"conditions":128,"interventions":130},"ACTIVE_NOT_RECRUITING",[55],"2020-10-19",40,[129],"Oligorecurrent and Oligoprogressive Prostate Cancer Patients",[48,131],"immune evaluation",{"intervention":131,"totalTrials":58,"cells":133},{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":140,"PHASE4":142,"NA":144},{"trials":135,"activeCount":62},[],{"trials":137,"activeCount":62},[],{"trials":139,"activeCount":62},[],{"trials":141,"activeCount":62},[],{"trials":143,"activeCount":62},[],{"trials":145,"activeCount":58,"soonestReadout":47},[146],{"nctId":45,"briefTitle":46,"status":124,"phases":147,"primaryCompletion":47,"completion":47,"start":126,"enrollment":127,"conditions":148,"interventions":149},[55],[129],[48,131],{"intervention":151,"totalTrials":58,"cells":152},"Azathioprine",{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":161,"NA":176},{"trials":154,"activeCount":62},[],{"trials":156,"activeCount":62},[],{"trials":158,"activeCount":62},[],{"trials":160,"activeCount":62},[],{"trials":162,"activeCount":62},[163],{"nctId":164,"briefTitle":165,"status":166,"phases":167,"primaryCompletion":168,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":174},"NCT03151525","Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis","UNKNOWN",[54],"2019-10-03","2020-04-03","2017-05-08",100,[173],"Colitis, Ulcerative",[151,175],"Infliximab",{"trials":177,"activeCount":62},[],{"intervention":175,"totalTrials":58,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":186,"PHASE4":188,"NA":194},{"trials":181,"activeCount":62},[],{"trials":183,"activeCount":62},[],{"trials":185,"activeCount":62},[],{"trials":187,"activeCount":62},[],{"trials":189,"activeCount":62},[190],{"nctId":164,"briefTitle":165,"status":166,"phases":191,"primaryCompletion":168,"completion":169,"start":170,"enrollment":171,"conditions":192,"interventions":193},[54],[173],[151,175],{"trials":195,"activeCount":62},[],{"intervention":197,"totalTrials":58,"cells":198},"Golimumab",{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":207,"NA":218},{"trials":200,"activeCount":62},[],{"trials":202,"activeCount":62},[],{"trials":204,"activeCount":62},[],{"trials":206,"activeCount":62},[],{"trials":208,"activeCount":62},[209],{"nctId":210,"briefTitle":211,"status":166,"phases":212,"primaryCompletion":213,"completion":214,"start":215,"enrollment":171,"conditions":216,"interventions":217},"NCT02412085","Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission",[54],"2016-12","2017-01","2015-03",[173],[197],{"trials":219,"activeCount":62},[],{"intervention":221,"totalTrials":58,"cells":222},"SKYRIZI",{"EARLY_PHASE1":223,"PHASE1":225,"PHASE2":227,"PHASE3":229,"PHASE4":231,"NA":243},{"trials":224,"activeCount":62},[],{"trials":226,"activeCount":62},[],{"trials":228,"activeCount":62},[],{"trials":230,"activeCount":62},[],{"trials":232,"activeCount":62},[233],{"nctId":234,"briefTitle":235,"status":166,"phases":236,"primaryCompletion":237,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":242},"NCT04722640","Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity",[54],"2022-01-31","2021-01-25",240,[241],"Psoriasis",[221],{"trials":244,"activeCount":62},[],{"intervention":246,"totalTrials":58,"cells":247},"PEG3350",{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":256,"NA":272},{"trials":249,"activeCount":62},[],{"trials":251,"activeCount":62},[],{"trials":253,"activeCount":62},[],{"trials":255,"activeCount":62},[],{"trials":257,"activeCount":62},[258],{"nctId":259,"briefTitle":260,"status":261,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":270},"NCT03742232","Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.","COMPLETED",[54],"2020-03-31","2018-10-31",399,[267,268,269],"Colon Polyp","Colon Adenoma","Colon Lesion",[246,271],"Macrogol 4000",{"trials":273,"activeCount":62},[],{"intervention":271,"totalTrials":58,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":290},{"trials":277,"activeCount":62},[],{"trials":279,"activeCount":62},[],{"trials":281,"activeCount":62},[],{"trials":283,"activeCount":62},[],{"trials":285,"activeCount":62},[286],{"nctId":259,"briefTitle":260,"status":261,"phases":287,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":288,"interventions":289},[54],[267,268,269],[246,271],{"trials":291,"activeCount":62},[],{"intervention":293,"totalTrials":294,"cells":295},"Rituximab",2,{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":313,"PHASE4":325,"NA":327},{"trials":297,"activeCount":62},[],{"trials":299,"activeCount":62},[],{"trials":301,"activeCount":62},[302],{"nctId":303,"briefTitle":304,"status":166,"phases":305,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":310,"interventions":312},"NCT05877040","A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy",[52],"2023-03-30","2023-09-30","2019-06-01",20,[311],"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",[293],{"trials":314,"activeCount":62},[315],{"nctId":316,"briefTitle":317,"status":261,"phases":318,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":324},"NCT06325943","Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy",[53],"2023-05-30","2023-11-30","2019-04-01",37,[311],[293],{"trials":326,"activeCount":62},[],{"trials":328,"activeCount":62},[],{"intervention":330,"totalTrials":58,"cells":331},"Parnaparin Sodium",{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":351,"NA":353},{"trials":333,"activeCount":62},[],{"trials":335,"activeCount":62},[],{"trials":337,"activeCount":62},[],{"trials":339,"activeCount":62},[340],{"nctId":341,"briefTitle":342,"status":343,"phases":344,"primaryCompletion":215,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":350},"NCT02991950","Weight Adjusted Low Molecular Weight Heparin in Recurrent Implantation Failure: a Randomized Open Labeled Trial","TERMINATED",[53],"2015-12","2011-07",271,[19,349],"Low Molecular Weight Heparin",[330],{"trials":352,"activeCount":62},[],{"trials":354,"activeCount":62},[],{"intervention":356,"totalTrials":58,"cells":357},"MK5172 \u002FMK8742",{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":377,"NA":379},{"trials":359,"activeCount":62},[],{"trials":361,"activeCount":62},[],{"trials":363,"activeCount":62},[],{"trials":365,"activeCount":62},[366],{"nctId":367,"briefTitle":368,"status":166,"phases":369,"primaryCompletion":213,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":376},"NCT02732405","Study to Investigate Tolerability and Efficacy of MK5172 \u002F MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis",[53],"2017-03","2016-05",120,[374,375],"Hepatitis C","Compensated Cirrhosis",[356],{"trials":378,"activeCount":62},[],{"trials":380,"activeCount":62},[],{"intervention":382,"totalTrials":294,"cells":383},"Sorafenib",{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":411,"PHASE4":413,"NA":415},{"trials":385,"activeCount":62},[],{"trials":387,"activeCount":62},[],{"trials":389,"activeCount":62},[390,400],{"nctId":391,"briefTitle":392,"status":261,"phases":393,"primaryCompletion":394,"start":395,"enrollment":396,"conditions":397,"interventions":399},"NCT00490685","Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)",[52],"2008-06","2007-04",142,[398],"Carcinoma, Hepatocellular",[382],{"nctId":401,"briefTitle":402,"status":261,"phases":403,"primaryCompletion":404,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":410},"NCT00406601","BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas",[52],"2010-06","2010-09","2006-11",69,[409],"Sarcoma, Soft Tissue",[382],{"trials":412,"activeCount":62},[],{"trials":414,"activeCount":62},[],{"trials":416,"activeCount":62},[],{"intervention":418,"totalTrials":58,"cells":419},"Ifosfamide, Gemcitabine, Vinorelbine",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":421,"activeCount":62},[],{"trials":423,"activeCount":62},[],{"trials":425,"activeCount":62},[426],{"nctId":427,"briefTitle":428,"status":261,"phases":429,"primaryCompletion":430,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":436},"NCT00636311","A Phase II Study of IGEV +\u002F- Bortezomib Before Hign Dose Consolidation in Relapsed\u002FRefractory Hodgkin's Lymphoma",[52],"2008-04","2010-02","2008-02",13,[435],"Hodgkin Disease",[418,437],"Bortezomib + IGEV",{"trials":439,"activeCount":62},[],{"trials":441,"activeCount":62},[],{"trials":443,"activeCount":62},[],{"intervention":437,"totalTrials":58,"cells":445},{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":456,"PHASE4":458,"NA":460},{"trials":447,"activeCount":62},[],{"trials":449,"activeCount":62},[],{"trials":451,"activeCount":62},[452],{"nctId":427,"briefTitle":428,"status":261,"phases":453,"primaryCompletion":430,"completion":431,"start":432,"enrollment":433,"conditions":454,"interventions":455},[52],[435],[418,437],{"trials":457,"activeCount":62},[],{"trials":459,"activeCount":62},[],{"trials":461,"activeCount":62},[],{"intervention":463,"totalTrials":58,"cells":464},"Vismodegib",{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":466,"activeCount":62},[],{"trials":468,"activeCount":62},[],{"trials":470,"activeCount":62},[471],{"nctId":472,"briefTitle":473,"status":343,"phases":474,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":479,"interventions":481},"NCT02956889","To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma",[52],"2019-02","2020-01","2016-10",14,[480],"Carcinoma, Basal Cell",[463],{"trials":483,"activeCount":62},[],{"trials":485,"activeCount":62},[],{"trials":487,"activeCount":62},[],{"intervention":489,"totalTrials":58,"cells":490},"nab-paclitaxel",{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":508,"PHASE4":510,"NA":512},{"trials":492,"activeCount":62},[],{"trials":494,"activeCount":62},[],{"trials":496,"activeCount":62},[497],{"nctId":498,"briefTitle":499,"status":166,"phases":500,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":507},"NCT03943043","Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer",[51,52],"2020-09-01","2021-05-01","2017-07-21",85,[506],"Cholangiocarcinoma",[489],{"trials":509,"activeCount":62},[],{"trials":511,"activeCount":62},[],{"trials":513,"activeCount":62},[],{"intervention":515,"totalTrials":58,"cells":516},"Thiotepa",{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":536,"PHASE4":538,"NA":540},{"trials":518,"activeCount":62},[],{"trials":520,"activeCount":62},[],{"trials":522,"activeCount":62},[523],{"nctId":524,"briefTitle":525,"status":166,"phases":526,"primaryCompletion":527,"completion":528,"start":529,"enrollment":530,"conditions":531,"interventions":533},"NCT02049580","Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas",[52],"2016-08","2016-11","2013-07",47,[532],"Lymphoma",[515,534,535],"Fludarabine","Cyclophosphamide",{"trials":537,"activeCount":62},[],{"trials":539,"activeCount":62},[],{"trials":541,"activeCount":62},[],{"intervention":534,"totalTrials":58,"cells":543},{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":554,"PHASE4":556,"NA":558},{"trials":545,"activeCount":62},[],{"trials":547,"activeCount":62},[],{"trials":549,"activeCount":62},[550],{"nctId":524,"briefTitle":525,"status":166,"phases":551,"primaryCompletion":527,"completion":528,"start":529,"enrollment":530,"conditions":552,"interventions":553},[52],[532],[515,534,535],{"trials":555,"activeCount":62},[],{"trials":557,"activeCount":62},[],{"trials":559,"activeCount":62},[],{"intervention":535,"totalTrials":58,"cells":561},{"EARLY_PHASE1":562,"PHASE1":564,"PHASE2":566,"PHASE3":572,"PHASE4":574,"NA":576},{"trials":563,"activeCount":62},[],{"trials":565,"activeCount":62},[],{"trials":567,"activeCount":62},[568],{"nctId":524,"briefTitle":525,"status":166,"phases":569,"primaryCompletion":527,"completion":528,"start":529,"enrollment":530,"conditions":570,"interventions":571},[52],[532],[515,534,535],{"trials":573,"activeCount":62},[],{"trials":575,"activeCount":62},[],{"trials":577,"activeCount":62},[],{"intervention":579,"totalTrials":58,"cells":580},"Gemcitabine",{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":598,"PHASE4":600,"NA":602},{"trials":582,"activeCount":62},[],{"trials":584,"activeCount":62},[],{"trials":586,"activeCount":62},[587],{"nctId":588,"briefTitle":589,"status":261,"phases":590,"primaryCompletion":345,"completion":591,"start":592,"enrollment":593,"conditions":594,"interventions":596},"NCT02303899","Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma",[52],"2017-12","2014-11",22,[595],"Mesothelioma, Malignant",[579,597],"Imatinib mesylate",{"trials":599,"activeCount":62},[],{"trials":601,"activeCount":62},[],{"trials":603,"activeCount":62},[],{"intervention":597,"totalTrials":58,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":616,"PHASE4":618,"NA":620},{"trials":607,"activeCount":62},[],{"trials":609,"activeCount":62},[],{"trials":611,"activeCount":62},[612],{"nctId":588,"briefTitle":589,"status":261,"phases":613,"primaryCompletion":345,"completion":591,"start":592,"enrollment":593,"conditions":614,"interventions":615},[52],[595],[579,597],{"trials":617,"activeCount":62},[],{"trials":619,"activeCount":62},[],{"trials":621,"activeCount":62},[],{"intervention":623,"totalTrials":58,"cells":624},"Methylprednisolone",{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":644,"PHASE4":646,"NA":648},{"trials":626,"activeCount":62},[],{"trials":628,"activeCount":62},[],{"trials":630,"activeCount":62},[631],{"nctId":632,"briefTitle":633,"status":343,"phases":634,"primaryCompletion":635,"completion":636,"start":637,"enrollment":72,"conditions":638,"interventions":642},"NCT01726465","Methylprednisolone N Acetylcysteine in Hepatic Resections",[52],"2013-10","2013-11","2012-11",[639,640,641],"Ischemic Reperfusion Injury","Insufficiency; Hepatic, Postoperative","Liver Tumour",[623,643],"N-acetylcysteine",{"trials":645,"activeCount":62},[],{"trials":647,"activeCount":62},[],{"trials":649,"activeCount":62},[],{"intervention":643,"totalTrials":58,"cells":651},{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":662,"PHASE4":664,"NA":666},{"trials":653,"activeCount":62},[],{"trials":655,"activeCount":62},[],{"trials":657,"activeCount":62},[658],{"nctId":632,"briefTitle":633,"status":343,"phases":659,"primaryCompletion":635,"completion":636,"start":637,"enrollment":72,"conditions":660,"interventions":661},[52],[639,640,641],[623,643],{"trials":663,"activeCount":62},[],{"trials":665,"activeCount":62},[],{"trials":667,"activeCount":62},[],{"intervention":669,"totalTrials":58,"cells":670},"Sunitinib",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":687,"PHASE4":689,"NA":691},{"trials":672,"activeCount":62},[],{"trials":674,"activeCount":62},[],{"trials":676,"activeCount":62},[677],{"nctId":678,"briefTitle":679,"status":261,"phases":680,"primaryCompletion":681,"completion":681,"start":682,"enrollment":683,"conditions":684,"interventions":686},"NCT01034878","Sunitinib in Metastatic Renal Cancer",[52],"2014-12","2009-12",25,[685],"Carcinoma, Renal Cell",[669],{"trials":688,"activeCount":62},[],{"trials":690,"activeCount":62},[],{"trials":692,"activeCount":62},[],{"intervention":694,"totalTrials":58,"cells":695},"Lenalidomide and dexamethasone",{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":711,"PHASE4":713,"NA":715},{"trials":697,"activeCount":62},[],{"trials":699,"activeCount":62},[],{"trials":701,"activeCount":62},[702],{"nctId":703,"briefTitle":704,"status":166,"phases":705,"primaryCompletion":682,"completion":346,"start":706,"enrollment":707,"conditions":708,"interventions":710},"NCT00971685","The Treatment of Lenalidomide in Patients With POEMS Syndrome",[52],"2009-07",16,[709],"POEMS Syndrome",[694],{"trials":712,"activeCount":62},[],{"trials":714,"activeCount":62},[],{"trials":716,"activeCount":62},[],{"intervention":718,"totalTrials":58,"cells":719},"SBRT and chemotherapy",{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":735,"PHASE4":737,"NA":739},{"trials":721,"activeCount":62},[],{"trials":723,"activeCount":62},[],{"trials":725,"activeCount":62},[726],{"nctId":727,"briefTitle":728,"status":261,"phases":729,"primaryCompletion":730,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":734},"NCT03158779","Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer",[52],"2022-07-01","2017-05-10",45,[26],[718],{"trials":736,"activeCount":62},[],{"trials":738,"activeCount":62},[],{"trials":740,"activeCount":62},[],{"intervention":742,"totalTrials":58,"cells":743},"Regorafenib",{"EARLY_PHASE1":744,"PHASE1":746,"PHASE2":748,"PHASE3":765,"PHASE4":767,"NA":769},{"trials":745,"activeCount":62},[],{"trials":747,"activeCount":62},[],{"trials":749,"activeCount":62},[750],{"nctId":751,"briefTitle":752,"status":261,"phases":753,"primaryCompletion":591,"completion":754,"start":681,"enrollment":755,"conditions":756,"interventions":764},"NCT02307500","Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy",[52],"2020-08",82,[757,758,759,760,761,762,763],"Pancreas Cancer","Ovarian Cancer","Melanoma","Sarcoma","Thymoma Type B3","Thymoma Type B2","Thymic Carcinoma",[742],{"trials":766,"activeCount":62},[],{"trials":768,"activeCount":62},[],{"trials":770,"activeCount":62},[],{"intervention":772,"totalTrials":58,"cells":773},"combination of TLC D-99 and Ifosfamide",{"EARLY_PHASE1":774,"PHASE1":776,"PHASE2":778,"PHASE3":788,"PHASE4":790,"NA":792},{"trials":775,"activeCount":62},[],{"trials":777,"activeCount":62},[],{"trials":779,"activeCount":62},[780],{"nctId":781,"briefTitle":782,"status":261,"phases":783,"primaryCompletion":682,"completion":682,"start":784,"enrollment":785,"conditions":786,"interventions":787},"NCT00289809","TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients",[51,52],"2006-09",36,[409],[772],{"trials":789,"activeCount":62},[],{"trials":791,"activeCount":62},[],{"trials":793,"activeCount":62},[],{"intervention":795,"totalTrials":58,"cells":796},"Cabozantinib 60 MG",{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":814,"PHASE4":816,"NA":818},{"trials":798,"activeCount":62},[],{"trials":800,"activeCount":62},[],{"trials":802,"activeCount":62},[803],{"nctId":804,"briefTitle":805,"status":166,"phases":806,"primaryCompletion":807,"completion":808,"start":809,"enrollment":810,"conditions":811,"interventions":813},"NCT04435977","Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma",[52],"2023-06","2023-09","2020-01-30",46,[812],"Hepatocarcinoma",[795],{"trials":815,"activeCount":62},[],{"trials":817,"activeCount":62},[],{"trials":819,"activeCount":62},[],{"intervention":821,"totalTrials":58,"cells":822},"Ferric carboxymaltose",{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":838,"PHASE4":840,"NA":842},{"trials":824,"activeCount":62},[],{"trials":826,"activeCount":62},[],{"trials":828,"activeCount":62},[829],{"nctId":830,"briefTitle":831,"status":166,"phases":832,"primaryCompletion":371,"completion":213,"start":833,"enrollment":785,"conditions":834,"interventions":837},"NCT02517151","Iron Supplementation in Inflammatory Bowel Disease (IBD) Patients With Chronic Fatigue",[52],"2014-10",[835,836],"Chronic Fatigue","Inflammatory Bowel Disease",[821],{"trials":839,"activeCount":62},[],{"trials":841,"activeCount":62},[],{"trials":843,"activeCount":62},[],{"intervention":845,"totalTrials":58,"cells":846},"Lapatinib and Sorafenib",{"EARLY_PHASE1":847,"PHASE1":849,"PHASE2":862,"PHASE3":864,"PHASE4":866,"NA":868},{"trials":848,"activeCount":62},[],{"trials":850,"activeCount":62},[851],{"nctId":852,"briefTitle":853,"status":261,"phases":854,"primaryCompletion":855,"completion":856,"start":857,"enrollment":858,"conditions":859,"interventions":861},"NCT00984425","The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors",[51],"2012-07","2013-08","2009-09",30,[860],"Solid Tumors",[845],{"trials":863,"activeCount":62},[],{"trials":865,"activeCount":62},[],{"trials":867,"activeCount":62},[],{"trials":869,"activeCount":62},[],{"intervention":871,"totalTrials":58,"cells":872},"Pre-implantation genetic testing",{"EARLY_PHASE1":873,"PHASE1":875,"PHASE2":877,"PHASE3":879,"PHASE4":881,"NA":883},{"trials":874,"activeCount":62},[],{"trials":876,"activeCount":62},[],{"trials":878,"activeCount":62},[],{"trials":880,"activeCount":62},[],{"trials":882,"activeCount":62},[],{"trials":884,"activeCount":62},[885],{"nctId":886,"briefTitle":887,"status":261,"phases":888,"primaryCompletion":889,"completion":889,"start":890,"enrollment":891,"conditions":892,"interventions":895},"NCT05936749","Pre-implantation Genetic Testing for Monogenic Disease: Single Center Experience",[],"2022-12-12","2016-01-02",76,[893,894],"Genetic Disease","Aneuploidy",[871],{"intervention":897,"totalTrials":58,"cells":898},"Radiosensitive therapy",{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":900,"activeCount":62},[],{"trials":902,"activeCount":62},[],{"trials":904,"activeCount":62},[],{"trials":906,"activeCount":62},[],{"trials":908,"activeCount":62},[],{"trials":910,"activeCount":62},[911],{"nctId":912,"briefTitle":913,"status":261,"phases":914,"primaryCompletion":915,"completion":915,"start":916,"enrollment":917,"conditions":918,"interventions":920},"NCT02567539","Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma",[55],"2022-06","2015-05-27",88,[919],"Recurrent High Grade Glioma",[897],{"intervention":922,"totalTrials":58,"cells":923},"Controlled ovarian stimulation",{"EARLY_PHASE1":924,"PHASE1":926,"PHASE2":928,"PHASE3":930,"PHASE4":932,"NA":934},{"trials":925,"activeCount":62},[],{"trials":927,"activeCount":62},[],{"trials":929,"activeCount":62},[],{"trials":931,"activeCount":62},[],{"trials":933,"activeCount":62},[],{"trials":935,"activeCount":62},[936],{"nctId":937,"briefTitle":938,"status":261,"phases":939,"primaryCompletion":940,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":945},"NCT03822429","Cumulative Live Birth Rate (CLBR) After a Complete IVF Cycle: a Single Center Retrospective Study",[],"2015-12-31","2010-01-01",6375,[30,944],"Fertility Disorders",[922],{"intervention":947,"totalTrials":58,"cells":948},"hCG administration before embryo transfer",{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":959},{"trials":950,"activeCount":62},[],{"trials":952,"activeCount":62},[],{"trials":954,"activeCount":62},[],{"trials":956,"activeCount":62},[],{"trials":958,"activeCount":62},[],{"trials":960,"activeCount":62},[961],{"nctId":962,"briefTitle":963,"status":261,"phases":964,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":971},"NCT03581422","Natural Cycles With Spontaneous Versus Induced Ovulation in FET",[],"2015-06-15","2017-12-31","2012-01-01",2866,[970],"Embryo Transfer",[947],{"intervention":973,"totalTrials":58,"cells":974},"Fluorescent in-situ hybridization",{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":981,"PHASE4":983,"NA":985},{"trials":976,"activeCount":62},[],{"trials":978,"activeCount":62},[],{"trials":980,"activeCount":62},[],{"trials":982,"activeCount":62},[],{"trials":984,"activeCount":62},[],{"trials":986,"activeCount":62},[987],{"nctId":988,"briefTitle":989,"status":166,"phases":990,"primaryCompletion":857,"completion":682,"start":991,"enrollment":171,"conditions":992,"interventions":994},"NCT00874146","Level of HER2-neu Gene Amplification an Response to Trastuzumab",[],"2009-03",[993],"Advanced Breast Cancer",[973],{"intervention":996,"totalTrials":58,"cells":997},"GnRH agonist",{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":999,"activeCount":62},[],{"trials":1001,"activeCount":62},[],{"trials":1003,"activeCount":62},[],{"trials":1005,"activeCount":62},[],{"trials":1007,"activeCount":62},[],{"trials":1009,"activeCount":62},[1010],{"nctId":1011,"briefTitle":1012,"status":261,"phases":1013,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":347,"conditions":1016,"interventions":1018},"NCT03837223","RESCUE PROTOCOL AND FRESH EMBRYO TRANSFER",[],"2016-12-31","2013-03-01",[1017],"GnRH Trigger and Rescue Protocol",[996],{"intervention":1020,"totalTrials":58,"cells":1021},"Acetic Acid",{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1028,"PHASE4":1030,"NA":1032},{"trials":1023,"activeCount":62},[],{"trials":1025,"activeCount":62},[],{"trials":1027,"activeCount":62},[],{"trials":1029,"activeCount":62},[],{"trials":1031,"activeCount":62},[],{"trials":1033,"activeCount":62},[1034],{"nctId":1035,"briefTitle":1036,"status":166,"phases":1037,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":1042,"interventions":1045},"NCT02231385","Acetic Acid Colonoscopy Enhancement Study",[55],"2015-01","2015-06","2014-09",500,[16,1043,1044],"Serrated Adenomas","Colon Nos Polypectomy Tubular Adenoma",[1020],{"intervention":1047,"totalTrials":58,"cells":1048},"Budesonide Orodispersible",{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1055,"PHASE4":1057,"NA":1059},{"trials":1050,"activeCount":62},[],{"trials":1052,"activeCount":62},[],{"trials":1054,"activeCount":62},[],{"trials":1056,"activeCount":62},[],{"trials":1058,"activeCount":62},[],{"trials":1060,"activeCount":62},[1061],{"nctId":1062,"briefTitle":1063,"status":261,"phases":1064,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1068,"interventions":1070},"NCT05594849","Evaluation of Efficacy, Safety and Patient' Satisfaction of Therapeutic Switch From Off-Steroids to Budesonide",[],"2023-10-30","2022-12-01",31,[1069],"Eosinophilic Esophagitis",[1047],{"intervention":1072,"totalTrials":58,"cells":1073},"Probiotic Formula",{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1080,"PHASE4":1082,"NA":1084},{"trials":1075,"activeCount":62},[],{"trials":1077,"activeCount":62},[],{"trials":1079,"activeCount":62},[],{"trials":1081,"activeCount":62},[],{"trials":1083,"activeCount":62},[],{"trials":1085,"activeCount":62},[1086],{"nctId":1087,"briefTitle":1088,"status":261,"phases":1089,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":17,"conditions":1092,"interventions":1094},"NCT05663060","Evaluation Study of the Intestinal Microbiota and Quality of Life in Patients Suffering From IBS Treated With Bifidice",[55],"2023-12-31","2022-12-13",[1093],"Irritable Bowel Syndrome",[1072],{"intervention":1096,"totalTrials":58,"cells":1097},"modified donor lymphocytes",{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1108},{"trials":1099,"activeCount":62},[],{"trials":1101,"activeCount":62},[],{"trials":1103,"activeCount":62},[],{"trials":1105,"activeCount":62},[],{"trials":1107,"activeCount":62},[],{"trials":1109,"activeCount":62},[1110],{"nctId":1111,"briefTitle":1112,"status":261,"phases":1113,"primaryCompletion":1114,"completion":1114,"start":1115,"enrollment":1116,"conditions":1117,"interventions":1123},"NCT04687982","Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).",[55],"2020-01-08","2018-11-13",19,[1118,1119,1120,1121,1122],"Bone Marrow Transplant Infection","Bone Marrow Transplant Complications","Graft Vs Host Disease","Infection","Hematological Malignancy",[1096],{"intervention":1125,"totalTrials":58,"cells":1126},"Gene mutations analysis and FISH",{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1131,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1128,"activeCount":62},[],{"trials":1130,"activeCount":62},[],{"trials":1132,"activeCount":62},[],{"trials":1134,"activeCount":62},[],{"trials":1136,"activeCount":62},[],{"trials":1138,"activeCount":62},[1139],{"nctId":1140,"briefTitle":1141,"status":261,"phases":1142,"primaryCompletion":1143,"completion":394,"start":1144,"enrollment":504,"conditions":1145,"interventions":1147},"NCT00491140","Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab",[],"2007-05","2006-12",[1146],"Colorectal Neoplasms",[1125],{"intervention":1149,"totalTrials":58,"cells":1150},"Gene mutation analyses and FISH",{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1157,"PHASE4":1159,"NA":1161},{"trials":1152,"activeCount":62},[],{"trials":1154,"activeCount":62},[],{"trials":1156,"activeCount":62},[],{"trials":1158,"activeCount":62},[],{"trials":1160,"activeCount":62},[],{"trials":1162,"activeCount":62},[1163],{"nctId":1164,"briefTitle":1165,"status":261,"phases":1166,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":1171,"interventions":1172},"NCT00740532","Molecular Features Predicting Response\u002FResistance to Trastuzumab in Metastatic Breast Cancer Patients",[],"2008-03","2010-08","2007-10",11,[28],[1149],{"intervention":1174,"totalTrials":58,"cells":1175},"Genome-wide association study",{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1182,"PHASE4":1184,"NA":1186},{"trials":1177,"activeCount":62},[],{"trials":1179,"activeCount":62},[],{"trials":1181,"activeCount":62},[],{"trials":1183,"activeCount":62},[],{"trials":1185,"activeCount":62},[],{"trials":1187,"activeCount":62},[1188],{"nctId":1189,"briefTitle":1190,"status":166,"phases":1191,"primaryCompletion":1192,"completion":1192,"start":1193,"enrollment":1194,"conditions":1195,"interventions":1197},"NCT06325878","Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy",[55],"2025-12-31","2022-11-15",3500,[1196],"Chronic Inflammatory Demyelinating Polyradiculoneuropathy",[1174],{"intervention":1199,"totalTrials":58,"cells":1200},"Subchondral and intra-articular injection of BMC",{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1207,"PHASE4":1209,"NA":1211},{"trials":1202,"activeCount":62},[],{"trials":1204,"activeCount":62},[],{"trials":1206,"activeCount":62},[],{"trials":1208,"activeCount":62},[],{"trials":1210,"activeCount":62},[],{"trials":1212,"activeCount":62},[1213],{"nctId":1214,"briefTitle":1215,"status":166,"phases":1216,"primaryCompletion":1217,"completion":1218,"start":1219,"enrollment":683,"conditions":1220,"interventions":1223},"NCT03790189","Subchondral and Intra-articular Application of Bone Marrow Concentrate for Knee Unicompartmental OA",[55],"2021-07","2021-11","2019-01",[1221,1222],"Osteoarthritis, Knee","Cartilage Degeneration",[1199]]